A Study of Oral Tazemetostat in Subjects With Moderate and Severe Liver Impairment With Advanced solid tumors or hematological malignancies

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517141-13-00

Acronym

EZH-1201

Enrollment

Registered

2024-10-17

Start date

2020-10-07

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Poland, Slovakia

None listed

Source: EU CTIS · Data processed: Feb 4, 2026